A Study of LY4101174 in Participants With Recurrent, Advanced or Metastatic Solid Tumors
← catalyst calendarNCT06238479 · readout ≤ 224 d
Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
490estimated
Sites
28
Countries
Australia, Belgium, China +4
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-03-05 | actual | When the study began enrolling |
| Primary completion | Mar 2027 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Apr 2027 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-02 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-22 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Metastatic Solid Tumor
- Recurrent Solid Tumor
- Advanced Solid Tumor
- Urinary Bladder Neoplasm
- Triple Negative Breast Cancer
- Non-small Cell Lung Cancer
- Esophageal Cancer
- Pancreatic Cancer
- Ovarian Cancer
- Cervical Cancer
- Head and Neck Squamous Cell Carcinoma
- Prostate Cancer
- Renal Pelvis Cancer
- Bladder Cancer
Intervention
- Drug: LY4101174
Primary outcomes
what the primary-completion date above is the date OFPhase 1a: To determine the recommended dose of LY4101174
measured First 2 Cycles (28 days)
Phase 1a: To determine the recommended phase 2 dose (RP2D) or optimal dose of LY4101174
measured First 2 Cycles (28 days)
Phase 1b: To assess the antitumor activity of LY4101174 Monotherapy: Overall response rate (ORR)
measured Up to Approximately 48 Months or 4 Years
Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed